Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires Contract Research Organization to Perform Important GLP-1 Human Pilot Study
- Lexaria, a global innovator in drug delivery platforms, recently hired a Contract Research Organization to perform their second GLP-1 human pilot study which will test a dissolvable DehydraTECH-GLP-1 oral dose formulation
- The announcement follows Lexaria’s WEIGHT-A24-1 animal study announcement examining diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and cannabidiol alone and in combination
- The move aligns with the company’s resolve to focus on their ability to enhance the delivery of GLP-1 diabetes and obesity drugs
At the beginning of the year, Lexaria Bioscience (NASDAQ: LEXX), a global innovator for enhanced drug delivery platforms, announced its intention to double down on GLP-1 clinical studies for the 2024 calendar year. This followed a successful, active year of R&D in 2023, which saw impressive results from its patented DehydraTECH(TM) technology for the improved delivery of GLP-1 agonists (glucagon-like peptide 1) used to treat type 2 diabetes and weight loss. According to Chris Bunka, the company’s CEO, these initial results fueled the management’s optimism in this new direction, emphasizing its superior pharmacokinetics and safety/efficacy performance of GLP-1 drugs when formulated with the technology.
“Given the overwhelming interest in the GLP-1 sector, this will be a main focus. We are not at this time planning additional 2024 research in the antiviral, nicotine, or PDE5 sectors. We have solid early-stage data in each of those areas that will allow us to build upon those at the right time,” noted Mr. Bunka (https://nnw.fm/nMODk ).
In early March, Lexaria announced a 12-week animal study, WEIGHT-A24-1, to examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol alone and in combination. The study, which will have 12 study arms, will involve a total rat population of 72 animals, with over 1,500 blood plasma samples collected over the duration of the study. Lexaria looks to build on the success of previous animal studies, which demonstrated, through brain tissue examination, that DehydraTECH can enable higher levels of drug delivery across the blood-brain-barrier and directly into the brain tissue (https://nnw.fm/uPe5L ).
Everything is on track with this and other studies, with Lexaria hiring a contract research organization (“CRO”) to perform the second DehydraTECH-powered GLP-1 human pilot study. This randomized, crossover, placebo-controlled investigation will compare three dose formulations, each at a 7 mg semaglutide dose. So far, the manufacturing of the test articles is expected to be completed within 30 days, although Independent Review Board approval will be required before the study commences (https://nnw.fm/qM8HN ).
“DehydraTECH has previously shown an ability to improve the delivery of certain drugs destined for the bloodstream through the buccal/sublingual tissues of the mouth and throat,” noted Mr. Bunka. “If this new study is successful in demonstrating efficacy and safety, the potential for a new era in GLP-1 delivery without the need for painful injections or stomach-upsetting tablets could be within reach,” he added.
These milestones highlight Lexaria’s confidence in its DehydraTECH technology for enhancing drug delivery, and its understanding of its potential in the GLP-1 industry.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria, a global innovator in drug delivery platforms, recently hired a Contract Research Organization to perform their second GLP-1 human pilot study which will test a dissolvable DehydraTECH-GLP-1 oral dose formulation
- The announcement follows Lexaria’s WEIGHT-A24-1 animal study announcement examining diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and cannabidiol alone and in combination
- The move aligns with the company’s resolve to focus on their ability to enhance the delivery of GLP-1 diabetes and obesity drugs
At the beginning of the year, Lexaria Bioscience (NASDAQ: LEXX), a global innovator for enhanced drug delivery platforms, announced its intention to double down on GLP-1 clinical studies for the 2024 calendar year. This followed a successful, active year of R&D in 2023, which saw impressive results from its patented DehydraTECH(TM) technology for the improved delivery of GLP-1 agonists (glucagon-like peptide 1) used to treat type 2 diabetes and weight loss. According to Chris Bunka, the company’s CEO, these initial results fueled the management’s optimism in this new direction, emphasizing its superior pharmacokinetics and safety/efficacy performance of GLP-1 drugs when formulated with the technology.
“Given the overwhelming interest in the GLP-1 sector, this will be a main focus. We are not at this time planning additional 2024 research in the antiviral, nicotine, or PDE5 sectors. We have solid early-stage data in each of those areas that will allow us to build upon those at the right time,” noted Mr. Bunka (https://nnw.fm/nMODk ).
In early March, Lexaria announced a 12-week animal study, WEIGHT-A24-1, to examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol alone and in combination. The study, which will have 12 study arms, will involve a total rat population of 72 animals, with over 1,500 blood plasma samples collected over the duration of the study. Lexaria looks to build on the success of previous animal studies, which demonstrated, through brain tissue examination, that DehydraTECH can enable higher levels of drug delivery across the blood-brain-barrier and directly into the brain tissue (https://nnw.fm/uPe5L ).
Everything is on track with this and other studies, with Lexaria hiring a contract research organization (“CRO”) to perform the second DehydraTECH-powered GLP-1 human pilot study. This randomized, crossover, placebo-controlled investigation will compare three dose formulations, each at a 7 mg semaglutide dose. So far, the manufacturing of the test articles is expected to be completed within 30 days, although Independent Review Board approval will be required before the study commences (https://nnw.fm/qM8HN ).
“DehydraTECH has previously shown an ability to improve the delivery of certain drugs destined for the bloodstream through the buccal/sublingual tissues of the mouth and throat,” noted Mr. Bunka. “If this new study is successful in demonstrating efficacy and safety, the potential for a new era in GLP-1 delivery without the need for painful injections or stomach-upsetting tablets could be within reach,” he added.
These milestones highlight Lexaria’s confidence in its DehydraTECH technology for enhancing drug delivery, and its understanding of its potential in the GLP-1 industry.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
